1. Academic Validation
  2. Development of Protein Degradation Inducers of Androgen Receptor by Conjugation of Androgen Receptor Ligands and Inhibitor of Apoptosis Protein Ligands

Development of Protein Degradation Inducers of Androgen Receptor by Conjugation of Androgen Receptor Ligands and Inhibitor of Apoptosis Protein Ligands

  • J Med Chem. 2018 Jan 25;61(2):543-575. doi: 10.1021/acs.jmedchem.7b00168.
Norihito Shibata 1 Katsunori Nagai 2 Yoko Morita 2 Osamu Ujikawa 2 Nobumichi Ohoka 1 Takayuki Hattori 1 Ryokichi Koyama 2 Osamu Sano 2 Yasuhiro Imaeda 2 Hiroshi Nara 2 Nobuo Cho 2 Mikihiko Naito 1
Affiliations

Affiliations

  • 1 Divisions of Molecular Target and Gene Therapy Products, National Institute of Health Sciences , 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan.
  • 2 Pharmaceutical Research Division, Takeda Pharmaceutical Co. Ltd. , 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan.
Abstract

Targeted protein degradation using small molecules is a novel strategy for drug development. We have developed hybrid molecules named specific and nongenetic inhibitor of Apoptosis protein [IAP]-dependent protein erasers (SNIPERs) that recruit IAP ubiquitin ligases to degrade target proteins. Here, we show novel SNIPERs capable of inducing proteasomal degradation of the Androgen Receptor (AR). Through derivatization of the SNIPER(AR) molecule at the AR ligand and IAP ligand and linker, we developed 42a (SNIPER(AR)-51), which shows effective protein knockdown activity against AR. Consistent with the degradation of the AR protein, 42a inhibits AR-mediated gene expression and proliferation of androgen-dependent prostate Cancer cells. In addition, 42a efficiently induces Caspase activation and Apoptosis in prostate Cancer cells, which was not observed in the cells treated with AR antagonists. These results suggest that SNIPER(AR)s could be leads for an Anticancer drug against prostate cancers that exhibit AR-dependent proliferation.

Figures
Products